消息

In related news, Uniper has also agreed to purchase 100 MW from the Gennaker wind project in Germany, a 976.5 MW offshore wind farm that is set to become one of the largest in the Baltic Sea. This deal marks Uniper’s first offshore wind power purchase agreement and is seen as a strategic fit for the company’s growing PPA business. Uniper aims to re...

全文

Uniper has secured a significant renewable energy deal with Respect Energy, signing a six‑year agreement to purchase 100 % of the power generated from four Uniper photovoltaic projects in Poland. The combined capacity of these projects is 219 MWp. This agreement aligns with Uniper’s broader strategy to expand its renewables business, following an i...

全文

Vivani Medical (VANI) said Tuesday that Novo Nordisk (NVO) will conduct an internal evaluation of NPM‑139, Vivani's semaglutide drug implant intended for chronic weight management, under a new agreement. The company said the agreement does not include exclusivity provisions for NPM‑139 or its proprietary NanoPortal technology. Additionally, Vivani...

全文

Vivani's pipeline includes a portfolio of GLP‑1 based implants for metabolic diseases, including obesity and type 2 diabetes. These implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding daily or weekly administration challenges associated with oral and injectable medicat...

全文

This development is expected to provide valuable data on Vivani's NanoPortal implants under development, including NPM‑139, which could address a growing segment of patients who would prefer a convenient once‑ or twice‑yearly treatment option. The agreement with Novo Nordisk also underscores Vivani's proprietary NanoPortal technology and its potent...

全文

Vivani expects to initiate a Phase 1, randomized, first‑in‑human study evaluating NPM‑139 in mid‑2026, with Wegovy injections as an active comparator. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM‑139 to support the initiation of a Phase 2 dose‑ranging study pending successful results.

全文

Vivani Medical, Inc. (Nasdaq: VANI) has signed a new agreement with Novo Nordisk to enable the company to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management. This non‑exclusive internal evaluation is expected to further demonstrate Novo Nordisk's interest in evaluating Vivani's technology and its lead semaglutide appl...

全文

Despite the positive metrics, the stock fell 8 % to $20.41 on Tuesday as market sentiment shifted. The sell‑off was attributed to unfinalized credit support for the Anthropic lease and a perceived lack of near‑term catalysts. The investment‑grade credit backstop is still pending Anthropic’s choice of hardware vendor. Nevertheless, consensus analyst...

全文

Following the lease announcement, WULF shares rose by 4.86 % to $22.21, with trading volume 73.3 million shares, about 135 % above its three‑month average. Analysts responded by raising price targets: Needham lifted its target to $33, Rosenblatt to $30, and Bernstein maintained a $36 target, citing a 71 % upside from current levels. Citi assigned a...

全文

To free capital for further AI‑infrastructure projects, TeraWulf sold its 50.1 % stake in the Abernathy Joint Venture to a Fluidstack‑led investor group. The sale, completed in staged installments, valued the stake at approximately $530 million, exceeding the original $450 million investment and generating a profit. The proceeds are earmarked for d...

全文